Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy | Radiation Oncology | Full Text

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy | Radiation Oncology | Full Text

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy

Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor ...

Authors:Lukas Käsmann, Chukwuka Eze, Julian Taugner, Olarn Roengvoraphoj, Maurice Dantes, Nina-Sophie Schmidt-Hegemann, Sanziana Schiopu, Claus Belka and Farkhad Manapov

Citation:Radiation Oncology 2020 15:167

Content type:Review

 

Published on: 9 July 2020

• ViewFull Text
 
• ViewPDF